Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — UBS Global Life Sciences Conference 2011
36 slides from Jazz Pharmaceuticals's conference presentation, Sep 21, 2011
Slide 1: Filing under Rule 425 cover notice
Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Jazz Pharmaceuticals, Inc. Subject Company: Jazz Pharmaceuticals, Inc. SEC File No. of Jazz Pharmaceuticals, Inc.: 001-33500 The following includes the slides a
Slide 2: Additional Information and Where to Find It
Additional Information and Where to Find It In connection with the proposed transaction, Jazz Pharmaceuticals and Azur Pharma will be filing documents with the SEC, including the filing by Jazz Pharmaceuticals of a preliminary and definitive proxy statement/prospectus relating to the proposed transa
Slide 3: UBS Global Life Sciences Conference
UBS Global Life Sciences Conference Bruce Cozadd Chief Executive Officer September 20, 2011
Slide 4: Forward-Looking Statements
Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the business combination transaction between Jazz
Slide 5: Additional Information
Additional Information Additional Information and Where to Find It In connection with the proposed business combination transaction described in this presentation, Jazz Pharmaceuticals and Azur Pharma will be filing documents with the SEC, including the filing by Jazz Pharmaceuticals of a preliminar
Slide 6: Strategy to Build Shareholder Value
Strategy to Build Shareholder Value Pursue lower risk 3 development of Acquire additional specialty products 2 marketed or close to Invest percentage Grow Xyrem sales in approval products of sales longer-term 1 current indications Leverage our expertise Increased focus on and infrastructure achievin
Slide 7: Strategic Transaction with Azur Pharma
Strategic Transaction with Azur Pharma
Slide 8: Compelling Strategic and Financial Benefits
Compelling Strategic and Financial Benefits Strategic Benefits Projected Financial Benefits 1 • Diversified portfolio of CNS and • Accretive transaction women’s health products • Revenues >$475M • Increased scale and platform and cash flow >$200M in for growth Jazz first 12 months Pharmaceuticals pl
Slide 9: Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc Portfolio & Financial• 12 products currently marketed in US • >$475 million in revenues in first 12 months Projections • >$200 million in cash generated in first 12 months Ownership in • Jazz Pharmaceuticals: slightly under 80%; Azur Pharma: slightly over 20% Combined Compan
Slide 10: Azur Pharma – Compelling Fit With Jazz Pharmaceuticals
Azur Pharma – Compelling Fit With Jazz Pharmaceuticals • Strong commercial focus and expertise $100 Net Sales (Millions) in CNS and women’s health • Approximately 170 employees: $80 105 people in 3 US sales forces $60 across pain, psychiatry and $40 women’s health $20 16 person medical affairs team
Slide 11: A Growing, Diversified Product Portfolio
A Growing, Diversified Product Portfolio 2011 Estimated Revenues Stand Alone Jazz Pharmaceuticals, Inc. Pro forma Jazz Pharmaceuticals plc FazaClo LD 8% Other CNS FazaClo HD 1% Women’s 3% Health 10% Prialt 6% Luvox CR 13% Luvox CR 9% Xyrem 87% Xyrem 63% 9
Slide 12: Prialt - for Chronic Pain
Prialt - for Chronic Pain • 2010 net sales of $20M (marketed by Azur since May 2010) 1 • Onlynon-opioid intrathecal (IT)analgesic forseverechronicpain • Compelling growth opportunity with similar characteristics to Xyrem: – Requires high touch sales capability with heavy clinical emphasis – Currentl
Slide 13: FazaClo – for Treatment Resistant Schizophrenia
FazaClo – for Treatment Resistant Schizophrenia • 2010 net sales of $37M • Orally disintegrating clozapine tablets approved for management of treatment resistant 1 schizophrenia • 10% prescription share despite largely generic clozapine market • FazaClo High Dose (HD) launched September 2010 – More
Slide 14: Women’s Health Products - Targeting a Growing Market
Women’s Health Products - Targeting a Growing Market Net Sales Contribution 100% 80% 60% 40% 20% 0% 2009 2010 2011E Other Women’s Health Elestrin 1 • Diversified andbalanced setofsixproductswith2010netsalesof$27M 1 • Significant growthopportunity drivenbyElestrin , a topicalgelERTtherapy • Patents t
Slide 15: Current Business and Financial Overview
Current Business and Financial Overview
Slide 16: Xyrem - Strong Sales Growth
Xyrem - Strong Sales Growth 2010 Xyrem Sales $143M 2011 Guidance $215M-$225M1 $60 $56 $50 $43 $43 $40 $37 $34 $30 $20 $10 $0 2Q10 3Q10 4Q10 1Q11 2Q11 YOY Volume 8% 8% 6% 12% 11% Growth 1. Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results m
Slide 17: Xyrem is a Standard of Care in Narcolepsy
Xyrem is a Standard of Care in Narcolepsy • Only FDA-approved product for both cataplexy and excessive daytime sleepiness in patients with narcolepsy – Marketed in U.S. since 2002 – Marketed in major European countries by UCB and in Canada by Valeant • Currently used in ~8,700 U.S. patients, usually
Slide 18: The Burden of Narcolepsy
The Burden of Narcolepsy 1 • Affects 1 in 2000 in US 2 – multiple sclerosis and Parkinson's disease 3 – > cystic fibrosis • Although narcolepsy is thought to affect between 125,000 and 200,000 Americans, only about 50,000 4 arediagnosed • Key symptoms can be debilitating – Cataplexy occurs in 60%-10
Slide 19: Xyrem has Demonstrated Effect on Two Key Symptoms of Narcolepsy
Xyrem has Demonstrated Effect on Two Key Symptoms of Narcolepsy Improvement in Epworth Reduction in Weekly 1 Sleepiness Scale Cataplexy Attacks2 XYREM XYREM Placebo 6 g/night 9 g/night (n=59) (n=58) (n=47) Placebo (n=33) 0 0 XYREM 6 g/night (n=31) –3% XYREM 9 g/night (n=33) -10 -20 -28% -40 -20 –16%
Slide 20: Most Common Adverse Events in Controlled Studies of Xyrem
Most Common Adverse Events in Controlled Studies of Xyrem % of Patients (N=655) 1 2 3 Adverse Event Placebo Xyrem Nausea 4 19 Dizziness 4 18 Headache 15 18 Vomiting 1 8 Somnolence 4 6 4 Urinary incontinence <1 6 Nasopharyngitis 5 6 Label includes boxed warning that sodium oxybate is a central nervou
Slide 21: Strong Sodium Oxybate Patent Coverage
Strong Sodium Oxybate Patent Coverage Number Issue Date Expiration Date Distribution system patent* 7,765,106 7/27/2010 6/16/2024 Distribution system patent* 7,765,107 7/27/2010 6/16/2024 Distribution system patent 7,797,171 9/14/2010 6/16/2024 Distribution system patent* 7,668,730 2/23/2010 6/16/20
Slide 22: Current Xyrem Patient Coverage Distribution
Current Xyrem Patient Coverage Distribution* • Approximately 90% of insured patients have access Medicare Part D Medicaid Cash • Relatively low rates of required prior authorizations Patient 3% 9% 1% Asst Program • Low monthly out-of-pocket (OOP) 8% expenses – Over 70% of patients have monthly OOP o
Slide 23: Xyrem Growth Initiatives
Xyrem Growth Initiatives Increased Marketing Investment • New narcolepsy physician targets • Xyrem Success Program education • Patient services - Nursing program - Xyrem Patient Connection - Patient assistance programs Improve Market Penetration Over Time Current Patients = ~ 8,700 Approximately 17%
Slide 24: 2011 Guidance Reflects High Operating Leverage
2011 Guidance Reflects High Operating Leverage 1 2010-A 2011-G Total Product Sales $170M $247 –260M Xyrem $143M $215 –225M Luvox CR $27M $32 –35M SG&A and R&D Combined $95M $105 –110M GAAP Net Income $33M $123 –131M 2 Adjusted Net Income $61M $145 –153M GAAP EPS $0.83 $2.68 $ - 2.79 2 Adjusted EPS $
Slide 25: Compelling Strategic and Financial Benefits
Compelling Strategic and Financial Benefits Strategic Benefits Projected Financial Benefits 1 • Diversified portfolio of CNS and • Accretive transaction women’s health products • Revenues >$475M • Increased scale and platform and cash flow >$200M in for growth Jazz first 12 months Pharmaceuticals pl
Slide 26: Jazz Pharmaceuticals - Innovation that performs
) Jazz Pharmaceuticals Innovation that performs
Slide 27: Reconciliation of GAAP Net Income and EPS to Adjusted Net Income and EPS
Reconciliation of GAAP Net Income and EPS to Adjusted Net Income and EPS in Financial Results and Guidance 1 FY 2010 FY 2011G GAAP net income $33 $123-131 Add: Intangible asset amortization 8 7 Stock-based compensation expense 8 14 Non-cash interest expense 2 2 Loss on extinguishment of debt 12 - De
Slide 28: Xyrem (sodium oxybate) Boxed Warning
Xyrem (sodium oxybate) Boxed Warning !WARNING: Central nervous system depressant with abuse potential. Should not be used with alcohol or other CNS depressants. Sodium oxybate is GHB, a known drug of abuse. Abuse has been associated with some important central nervous system (CNS) adverse events (in
Slide 29: Prialt (ziconotide intrathecal infusion) Boxed Warning
Prialt (ziconotide intrathecal infusion) Boxed Warning WARNING: Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Patients with a pre-existing history of psychosis should not be treated with PRIALT. All patients should be monitored frequently forevidence
Slide 30: FazaClo (clozapine) Boxed Warning
FazaClo (clozapine) Boxed Warning WARNING: 1. AGRANULOCYTOSIS BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF SEVERELY ILL PATIENTS WITH SCHIZOPHRENIA WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE
Slide 31: FazaClo (clozapine) Boxed Warning - continued
FazaClo (clozapine) Boxed Warning - continued 4. OTHERADVERSECARDIOVASCULARANDRESPIRATORY EFFECTS ORTHOSTATIC HYPOTENSION, WITH OR WITHOUT SYNCOPE, CAN OCCUR WITH CLOZAPINE TREATMENT. RARELY, COLLAPSE CAN BE PROFOUND AND BE ACCOMPANIED BY RESPIRATORY AND/OR CARDIAC ARREST. ORTHOSTATIC HYPOTENSION IS
Slide 32: Jazz Pharmaceuticals - Innovation that performs
\ : | . ) Jazz Pharmaceuticals Innovation that performs
Slide 33: Transcript Jazz Pharmaceuticals, Inc. - Page 1
Page 1 Transcript Jazz Pharmaceuticals, Inc. September 20, 2011 9:30 AM ET Ami Fadia: Hello. Thanks for joining us. The next presentation is from Jazz Pharmaceuticals. I’m Ami Fadia, the (inaudible) tech pharma analyst at UBS and it’s my pleasure to invite Bruce Cozadd, the CEO at Jazz. Following th
Slide 34: Transcript - Page 2
Page 2 provides us with increased scale and a platform for future growth. Part of doing this transaction was not to look at what one transaction makes sense, but to set ourselves up to be able to do additional transactions in the future. It gives us a stronger base on which to execute our R&D strate
Slide 35: Transcript - Page 3
Page 3 competes in a large genericized clozapine market. Azur did launch a higher-dose version of FazaClo about a year ago and has switched over 20% from their lower dose strengths through the first half of this year. Doctors tell the company they appreciate the dosing flexibility and lower pill bur
Slide 36: Transcript - Page 4
Page 4 Xyrem. It is a CNS depressant and should not be used in combination with alcohol or other CNS depressants. The black box warning for Xyrem, as well as the other products with black box warnings, are included on the product websites. And if you go to our website and look at a copy of this pres
Jazz Pharmaceuticals — UBS Global Life Sciences Conference 2011 on 6ix